ARCHIVES

Phase III Trial Would Give Clearer Picture Of C225 Role.

This article is from The Cancer Letter archive.

Vol. 28 No. 07 | February 15, 2002

Download PDF Visit The Full Archive

Related Articles

FDA Approves Novartis Drug Zometa For Multiple Myeloma And Bone Mets.

March 1, 2002

NIH grant success rate drops to under 20 percent after 2011 budget cuts

May 13, 2011

Paul Goss, Patricia Ganz Discuss Breast Cancer Prevention Trials.

April 20, 2007

NCI Advisors Reject $30-Million Cohort Study, Approve Renewal of Phase I Clinical Trials Initiatives and American College of Radiology Imaging Network.

July 7, 2006

RFOs Available, Contract Awards, Sole Source Negotiations

February 3, 1978

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

March 21, 2008